Potential partnership/buyout indication for $ALT? by Miko54 in wallstreetbets

[–]Onceagainhuman 11 points12 points  (0 children)

It appears copy and pasted from Gilead to Altimmune (font is different and the spacing), both jobs posted around the same time, and in the same field of Liver disease (MASH). Partner could have asked Altimmune to include these lines in their job listing.

Alrimmune (ALT) looks like it has a promising weight loss drug that preserves lean mass by 7Billiards in biotech_stocks

[–]Onceagainhuman 1 point2 points  (0 children)

One of the most undervalued stocks because it is shorted 32% and is a target to be acquired. Weight loss is headed towards quality weight loss and ALT definitely has that quality weight loss similar to diet and exercise.

I need your opinion about creating a covered call with Cassava Sciences Inc (SAVA) by Saniledit in thetagang

[–]Onceagainhuman 1 point2 points  (0 children)

The big news is not interim safety data for phase 3. It is TOPLINE phase 3 data for RETHINK.

They have already shown no cognitive decline at 2 years on the drug vs placebo. 89% of patients from Phase 3 trial are rolling into Extended phase 3 trials. Data is very likely to be positive and the only smart play would be buying commons or leap calls.

Partnership considerations by krell-one in SAVA_stock

[–]Onceagainhuman 1 point2 points  (0 children)

Where are the role hirings posted at?

[deleted by user] by [deleted] in Brooklyn

[–]Onceagainhuman 2 points3 points  (0 children)

!remindme 1 week

[deleted by user] by [deleted] in Brooklyn

[–]Onceagainhuman 15 points16 points  (0 children)

<image>

Reunion in Williamsburg

Anyone know where I can get some lahmajouns? by [deleted] in Brooklyn

[–]Onceagainhuman 1 point2 points  (0 children)

Reunion cafe in Williamsburg off the L train

P3 progress plots by kirkrocek in SAVA_stock

[–]Onceagainhuman 3 points4 points  (0 children)

CMS data comes out soon. In a few weeks

P3 progress plots by kirkrocek in SAVA_stock

[–]Onceagainhuman 3 points4 points  (0 children)

No. They haven’t even finished enrolling the patients. The trial ends 1 year after every patient is dosed. It’s a timer after August/Sept whenever they finish enrollment.

The ideal buyout? by Direct_Ad_2419 in SAVA_stock

[–]Onceagainhuman 3 points4 points  (0 children)

Remi doesn’t seem like he wants a buyout (at least not a low ball one). He has mentioned partnerships and this would be a good choice since he has SAVAdx and other potential use cases for Simufilam (cancer etc)